AMCP Signs Joint Stakeholder Letter to the HHS OIG on Safe Harbor for Value-Based Contracts

The United States Pharmacopeia Convention (USP) and the United States Food and Drug Administration (FDA) have updated an educational resource on biosimilars to help healthcare practitioners improve patient confidence in the quality and effectiveness of these treatment options. The following are recommended social media, website, and email content you can use to share this resource with your network.

The aim of the AMCP Format is to identify comprehensive evidence and information elements that meet the evidentiary needs of HCDMs. The AMCP Format is designed to encourage sharing of objective, credible, and relevant information on medical products.